Tempest Therapeutics Inc
Change company Symbol lookup
Select an option...
TPST Tempest Therapeutics Inc
PETV PetVivo Holdings Inc
KMI Kinder Morgan Inc
NXPL NextPlat Corp
D Dominion Energy Inc
CVS CVS Health Corp
CVI CVR Energy Inc
CTRE CareTrust REIT Inc
CSWC Capital Southwest Corp
CSCO Cisco Systems Inc

Health Care : Biotechnology |
Company profile

Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a range of tumors. The Company’s two clinical programs include TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPARa). TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, and is in Phase I monotherapy and combination trials in solid tumors.

Closing Price
Day's Change
-0.20 (-9.76%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Illumina: It's not in the 'best interests' of shareholders to support Carl Icahn's nominees to the board

2:44 pm ET March 13, 2023 (MarketWatch)

Illumina Inc. (ILMN) said Monday it received notice from Icahn Partners that the organization plans to nominate three candidates to to the board over concerns about the company's $7.1 billion acquisition of Grail. Jesse Lynn and Andrew Teno are current Icahn employees and Vincent Intrieri is a former Icahn employee. Icahn reportedly told Illumina that the acquisition, which has faced regulatory scrutiny, cost shareholders $50 billion, according to the Wall Street Journal. The news rallied shares, which were up about 18% in trading on Monday afternoon. "It is not in the best interests of shareholders to appoint Mr. Icahn's three nominees to the board of Illumina," the company said. "The board recommends that shareholders not support Mr. Icahn's nominees." Illumina's stock is down 21.7% so far this year, while the broader S&P 500 is up about 1.0%.

-Jaimy Lee


This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

March 13, 2023 14:44 ET (18:44 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.